Christopher V. Plowe

Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine (2010)

Ouattara, Amed, Mu, Jianbing, Takala-Harrison, Shannon, Saye, Renion, Sagara, Issaka, Dicko, Alassane, ...

Abstract Background Extensive genetic diversity in vaccine antigens may contribute to the lack of efficacy of blood stage malaria vaccines. Apical membrane antigen-1 (AMA1) is a leading blood stage...

The rationale and plan for creating a World Antimalarial Resistance Network (WARN) (2007)

Sibley, Carol, Barnes, Karen I, Plowe, Christopher V

Abstract Drug resistant malaria was a major factor contributing to the failure of a worldwide campaign to eradicate malaria in the last century, and now threatens the large investment being made by...

World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria (2007)

Plowe, Christopher V, Roper, Cally, Barnwell, John W, Happi, Christian T, Joshi, Hema H, Mbacham, Wilfred, ...

Abstract Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to...

World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs (2007)

Price, Ric N, Dorsey, Grant, Ashley, Elizabeth A, Barnes, Karen I, Baird, J Kevin, D'Alessandro, Umberto, ...

Abstract The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The...

World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology (2007)

Barnes, Karen I, Lindegardh, Niklas, Ogundahunsi, Olumide, Olliaro, Piero, Plowe, Christopher V, Randrianarivelojosia, Milijaona, ...

Abstract A World Antimalarial Resistance Network (WARN) database has the potential to improve the treatment of malaria, through informing current drug selection and use and providing a prompt warning...

Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali (2007)

Shannon L. Takala, Drissa Coulibaly, Mahamadou A. Thera, Alassane Dicko, David L. Smith, Ando B. Guindo, ...

BackgroundMalaria vaccines based on the 19-kDa region of merozoite surface protein 1 (MSP-119) derived from the 3D7 strain of Plasmodium falciparum are being tested in clinical trials in Africa....

World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. (2007)

Plowe, Christopher V, Roper, Cally, Barnwell, John W, Happi, Christian T, Joshi, Hema H, Mbacham, Wilfred, ...

Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to...

Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial (2006)

Mahamadou A. Thera, Ogobara K. Doumbo, Drissa Coulibaly, Dapa A. Diallo, Issaka Sagara, Alassane Dicko, ...

Objectives:The objectives were to evaluate the safety, reactogenicity, and allele-specific immunogenicity of the blood-stage malaria vaccine FMP1/AS02A in adults exposed to seasonal malaria and the...

A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparummerozoite surface protein-1 19 kDa (2006)

Takala, Shannon L, Smith, David L, Stine, O Colin, Coulibaly, Drissa, Thera, Mahamadou A, Doumbo, Ogobara K, ...

Abstract Background Malaria vaccine efficacy may be compromised if the frequency of non-target alleles increases following vaccination with a genetically polymorphic target. Methods are needed to...

Towards an RTS,S-Based, Multi-Stage, Multi-Antigen Vaccine Against Falciparum Malaria: Progress at the Walter Reed Army Institute of Research (2005)

Heppner Jr., D. Gray, Kester, Kent E., Ockenhouse, Christian F., Tornieporth, Nadia, Ofori, Opokua, Lyon, Jeffrey A., ...

The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) is to develop a licensed multi-antigen, multi-stage vaccine against Plasmodium falciparum able to prevent...

Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria (2002)

Méndez, Fabián, Muñoz, Álvaro, Carrasquilla, Gabriel, Jurado, Diana, Arévalo-Herrera, Myriam, Cortese, Joseph F., ...

Drug resistance is contributing to increasing mortality from malaria worldwide. For assessment of the role of resistance-conferring parasite mutations on treatment responses to...

Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study

Plowe, Christopher V, Kublin, James G, Dzinjalamala, Fraction K, Kamwendo, Deborah S, Mukadam, Rabia A G, Chimpeni, Phillips, ...

Objective To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line...

Association between the Pharmacokinetics and In Vivo Therapeutic Efficacy of Sulfadoxine-Pyrimethamine in Malawian Children

Dzinjalamala, Fraction K., Macheso, Allan, Kublin, James G., Taylor, Terrie E., Barnes, Karen I., Molyneux, Malcolm E., ...

Sulfadoxine-pyrimethamine (SP) has been widely used in recent years to treat acute uncomplicated Plasmodium falciparum malaria. Risk factors for SP therapeutic failure include young age,...

HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls

Lyke, Kirsten E., Burges, Robin B., Cissoko, Yacouba, Sangare, Lansana, Kone, Abdoulaye, Dao, Modibo, ...

Understanding HLA-restricted adaptive host immunity to defined epitopes of malarial antigens may be required for the development of successful malaria vaccines. Fourteen epitopes of preerythrocytic...

Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study

Plowe, Christopher V, Kublin, James G, Dzinjalamala, Fraction K, Kamwendo, Deborah S, Mukadam, Rabia A G, Chimpeni, Phillips, ...

Objective To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line...

Association between the Pharmacokinetics and In Vivo Therapeutic Efficacy of Sulfadoxine-Pyrimethamine in Malawian Children

Dzinjalamala, Fraction K., Macheso, Allan, Kublin, James G., Taylor, Terrie E., Barnes, Karen I., Molyneux, Malcolm E., ...

Sulfadoxine-pyrimethamine (SP) has been widely used in recent years to treat acute uncomplicated Plasmodium falciparum malaria. Risk factors for SP therapeutic failure include young age,...

HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls

Lyke, Kirsten E., Burges, Robin B., Cissoko, Yacouba, Sangare, Lansana, Kone, Abdoulaye, Dao, Modibo, ...

Understanding HLA-restricted adaptive host immunity to defined epitopes of malarial antigens may be required for the development of successful malaria vaccines. Fourteen epitopes of preerythrocytic...

Effects of Concomitant Schistosoma haematobium Infection on the Serum Cytokine Levels Elicited by Acute Plasmodium falciparum Malaria Infection in Malian Children

Lyke, Kirsten E., Dabo, Abdoulaye, Sangare, Lansana, Arama, Charles, Daou, Modibo, Diarra, Issa, ...

Polyparasitism is common in the developing world, and interactions that alter disease severity may occur. We previously demonstrated that infection with Schistosoma hematobium was associated with...

Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali

Takala, Shannon L, Coulibaly, Drissa, Thera, Mahamadou A, Dicko, Alassane, Smith, David L, Guindo, Ando B, ...

Christopher Plowe and colleagues surveyed local malaria parasites for genetic diversity in MSP-1, a candidate vaccine antigen. These data are needed to interpret population responses to MSP-1-based...

The rationale and plan for creating a World Antimalarial Resistance Network (WARN)

Sibley, Carol Hopkins, Barnes, Karen I, Plowe, Christopher V

Drug resistant malaria was a major factor contributing to the failure of a worldwide campaign to eradicate malaria in the last century, and now threatens the large investment being made by the global...

World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs

Price, Ric N, Dorsey, Grant, Ashley, Elizabeth A, Barnes, Karen I, Baird, J Kevin, D'Alessandro, Umberto, ...

The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of...

World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria

Plowe, Christopher V, Roper, Cally, Barnwell, John W, Happi, Christian T, Joshi, Hema H, Mbacham, Wilfred, ...

Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to...

World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology

Barnes, Karen I, Lindegardh, Niklas, Ogundahunsi, Olumide, Olliaro, Piero, Plowe, Christopher V, Randrianarivelojosia, Milijaona, ...

A World Antimalarial Resistance Network (WARN) database has the potential to improve the treatment of malaria, through informing current drug selection and use and providing a prompt warning of when...

Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting

Rowe, J. Alexandra, Handel, Ian G., Thera, Mahamadou A., Deans, Anne-Marie, Lyke, Kirsten E., Koné, Abdoulaye, ...

Malaria has been a major selective force on the human population, and several erythrocyte polymorphisms have evolved that confer resistance to severe malaria. Plasmodium falciparum rosetting, a...

Pneumocystis Pneumonia in HIV-positive Adults, Malawi1

Laufer, Miriam K., Perez, M. Arantza, Graham, Stephen M., Chimbiya, Nelson, Thesing, Phillip C., ...

In a prospective study of 660 HIV-positive Malawian adults, we diagnosed Pneumocystis jirovecii pneumonia (PcP) using clinical features, induced sputum for immunofluorescent staining, real-time PCR,...

Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia

Kyriacou, Helen M., Stone, Graham N., Challis, Richard J., Raza, Ahmed, Lyke, Kirsten E., Thera, Mahamadou A., ...

The Plasmodium falciparum variant erythrocyte surface antigens known as PfEMP1, encoded by the var gene family, are thought to play a crucial role in malaria pathogenesis because they mediate...